{
    "nctId": "NCT03315364",
    "briefTitle": "Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy",
    "officialTitle": "A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel\u00ae (Oral Paclitaxel) Compared to Taxol\u00ae (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Recurrent or Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 549,
    "primaryOutcomeMeasure": "[Phase II] Objective Response Rate (ORR)",
    "eligibilityCriteria": "Key inclusion/exclusion criteria\n\n* Histologically or cytologically confirmed to have recurrent, or metastatic breast cancer.\n* Measurable disease (revised RECIST, version 1.1).\n* Hormone receptor (ER/PR) positive or negative, HER2 negative.\n* Subjects were eligible for the study regardless of their previous lines of endocrine therapy.\n* No prior chemotherapy is allowed in metastatic disease.\n* Subjects who administrated the last dose of taxane class drug \u226512months ago as from the first administration day.\n* ECOG performance status \u22641.\n* Neuropathy grade \\<2.\n* Subjects with central nervous system metastasis should be excluded.",
    "sex": "ALL",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}